CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.52B, above the global median of $1.15B
- PositionDebt-to-equity is 19.87×, higher than 95% of its Biotechnology peers (median 0.1×)
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.52BUSDvs all stocks (USD)
Trailing P/E
125.71xvs Biotechnology peers
Revenue (TTM)
314.85MUSDvs all stocks (USD)
Profit Margin
3.81%vs Biotechnology peers
Beta
0.8500xvs all stocks
52-Week Change
71.21%vs all stocks
Market Capitalization
1.52BUSDvs all stocks (USD)
Enterprise Value
1.67BUSDvs all stocks (USD)
Trailing P/E
125.71xvs Biotechnology peers
Forward P/E
22.42xvs Biotechnology peers
PEG Ratio
-1.08xvs Biotechnology peers
Price to Sales (TTM)
4.83xvs Biotechnology peers
Price to Book (MRQ)
107.32xvs Biotechnology peers
Enterprise to Revenue
5.29xvs Biotechnology peers
Enterprise to EBITDA
34.65xvs Biotechnology peers
Gross Margin
87.28%vs Biotechnology peers
Profit Margin
3.81%vs Biotechnology peers
Operating Margin
9.52%vs Biotechnology peers
Return on Assets (TTM)
6.34%vs Biotechnology peers
Return on Equity (TTM)
4.05%vs Biotechnology peers
Revenue (TTM)
314.85MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.91USDUpdated Jul 19, 2026Quarterly Revenue Growth
38.30%vs Biotechnology peers
Gross Profit (TTM)
270.44MUSDvs all stocks (USD)
EBITDA (TTM)
53.43MUSDvs all stocks (USD)
Net Income (TTM)
12.01MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
38.27%vs Biotechnology peers
Operating Cash Flow (TTM)
48.53MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
42.21MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
291.85MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
42.57MUSDFY2025 · Dec 31, 2025Gross Profit
249.28MUSDFY2025 · Dec 31, 2025Operating Income
24.90MUSDvs all stocks (USD)
Pre-tax Income
554.00KUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
554.00KUSDFY2025 · Dec 31, 2025EBIT
29.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
42.33MUSDFY2025 · Dec 31, 2025Research & Development
31.16MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
182.37MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
29.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.00USDFY2025 · Dec 31, 2025EPS (Diluted)
0.00USDFY2025 · Dec 31, 2025Basic Shares Outstanding
160.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
160.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
554.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
11.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
115.06MUSDFY2025 · Dec 31, 2025Interest Paid
27.12MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
554.00KUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.69MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
22.37MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.37MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.63MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-69.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.25MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-10.88MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.71MUSDFY2025 · Dec 31, 2025Shares Outstanding
172.56MSharesUpdated Jul 19, 2026Float Shares
166.28MSharesUpdated Jul 19, 2026Shares Short
12.76MSharesUpdated Jul 19, 2026Short Ratio
6.20daysvs all stocks
Short % of Shares Outstanding
7.65%vs all stocks
% Held by Insiders
3.38%vs all stocks
% Held by Institutions
62.60%vs all stocks
Total Cash (MRQ)
111.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6470USDUpdated Jul 19, 2026Total Debt (MRQ)
258.55MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
19.87xvs Biotechnology peers
Current Ratio (MRQ)
2.12xvs Biotechnology peers
Book Value per Share (MRQ)
0.0820USDUpdated Jul 19, 2026Total Assets
383.53MUSDvs all stocks (USD)
Total Current Assets
240.31MUSDFY2025 · Dec 31, 2025Total Liabilities
369.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
143.21MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
260.26MUSDFY2025 · Dec 31, 2025Total Current Liabilities
109.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
111.04MUSDFY2025 · Dec 31, 2025Accounts Receivable
51.05MUSDFY2025 · Dec 31, 2025Inventory
68.67MUSDFY2025 · Dec 31, 2025Accounts Payable
3.08MUSDFY2025 · Dec 31, 2025Short-term Debt
6.23MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.89MUSDFY2025 · Dec 31, 2025Long-term Debt
251.87MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
8.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-671.31MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
13.69MUSDvs all stocks (USD)
52-Week Low
4.87USDUpdated Jul 19, 202652-Week High
10.08USDUpdated Jul 19, 202652-Week Change
71.21%vs all stocks
Beta
0.8500xvs all stocks
50-Day MA
7.04USDUpdated Jul 19, 2026200-Day MA
7.07USDUpdated Jul 19, 2026Avg 10-Day Volume
2.00MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.18MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.0700USDUpdated Jul 19, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 19.87×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 19.87Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 107.32×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 107.317Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.87Profit Margin: 0.04
Financial Health
Altman Z-Score 1.44: grey zoneSignificant
Altman Z-Score: 1.44
High structural barrier to entryNotable
Barrier to Entry: 1.49
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.52B, above the global median of $1.15BNotable
Market cap (USD): 1,519,250,084Global Median: 1,146,734,693.424
Levered free cash flow is $42.21M, above the global median of $16.24MNotable
Levered free cash flow (USD): 42,205,376Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
7 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit
Alnylam Pharmaceuticals Inc.
6 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Designer Brands Inc.
5 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit